Followers | 31 |
Posts | 2603 |
Boards Moderated | 0 |
Alias Born | 02/18/2005 |
![](https://investorshub.advfn.com/uicon/53156.png?cb=1636020521)
Wednesday, August 05, 2020 8:44:37 AM
August 4, 2020
Severely ill COVID-19 patients given Relief Therapeutics’ RLF-100 (aviptadil) experienced rapid recovery in just three days, according to the company and its research partner NeuroRx.
The treatment, a patented formulation of synthetic human vasoactive intestinal polypeptide, works by inhibiting pro-inflammatory cytokines and protecting lung cells targeted by the coronavirus. It has been granted expanded access and a Fast Track designation by the FDA and is currently in an ongoing phase 2/3 trial.
The peptide hormone formulation led to fast recovery of COVID-19 patients with respiratory failure who were given access to the drug under the FDA’s emergency investigational new drug (IND) program.
Patients with critical COVID-19 “were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50 percent or greater average decrease in laboratory markers associated with COVID-19 inflammation,” the companies said.
Houston Methodist Hospital was the first to announce a rapid clinical recovery under the emergency use, the companies said. A 54-year-old COVID-19 patient was taken off a ventilator within four days of being treated with RLF-100. Similar results were reported for more than 15 patients treated under the FDA’s emergency use. — James Miessler
COVID-19
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM